ReviewExpert opinion on pharmacotherapy2017

Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.

Natalie Uy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.